Over the last year, diabetes technology saw significant changes, including the acceleration of patch pumps, ever-smaller continuous glucose monitors (CGM), implanted CGMs and increased interest in ...

Zenas Biopharma Inc.’s positive data from the phase III Indigo trial with obexelimab in immunoglobulin G4-related disease (IgG4-RD) set investigators to speculating about the bifunctional antibody’s ...

December 2025 was a big month for announcements from Psithera Inc. The Watertown, Mass.-based newco announced its name change ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, ...

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate ...

Four optimization trends dominated the med-tech industry in 2025. Growth-driven acquisitions propelled major players into hot ...

Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the ...

The U.S. FDA recently cleared Medtronic plc’s Hugo robotic-assisted surgery system and CMR Surgical Ltd.’s Versius Plus ...

In a recent publication in Molecular Therapy, researchers from Drexel University College of Medicine and UMass Chan Medical ...

After a volatile but ultimately strong year for biopharma stocks, 2025 delivered a mixed picture marked by sharp workforce reductions alongside resilient capital markets and high-value dealmaking.

BioWorld logged 170 clinical trial updates across phases I through III in November 2025, a decline from 252 updates in ...